Table 2. Change in CgA levels in 19 patients after discontinuation of PPIs treatment.

Patient	Sex, age (years)	Grade	Primary site	Status of disease	Carcinoid syndrome	GFR (ml per minute per 1.73 m2)	Replacement	CgA (μg l–1) during PPI	CgA (μg l–1) after PPI	CgA change (%)
1	F, 63	G1	Appendix	NED	NA	85	H2RA	425	120	−72
2	F, 51	G2	Lung	NED	NA	86	H2RA	307	42	−86
3	F, 54	G2	Lung	NED	NA	76	Stop	178	51	−71
4	F, 42	G1	Lung	NED	NA	72	Stop	123	15	−88
5	M, 65	G1	Small bowel	NED	NA	95	Stop	266	40	−85
6	F, 77	G1	Small bowel	NED	NA	93	Stop	1310	245	−81
7	F, 61	G1	Small bowel	NED	NA	50	Stop	1610	181	−89
8	F, 65	G1	Small bowel	NED	NA	77	H2RA	206	48	−77
9	M, 76	G1	Small bowel	NED	NA	90	H2RA	390	65	−83
10	F, 67	G1	Pancreas	NED	NA	102	Stop	404	56	−86
11	M, 75	G1	Small bowel	NED	NA	59	Stop	576	101	−82
12	M, 68	G1	Pancreas	SD	Yes	82	H2RA	1367	332	−76
13	F, 67	G1	Small bowel	SD	Yes	78	H2RA	588	148	−75
14	F, 50	G1	Pancreas	SD	No	78	Stop	1330	305	−77
15	F, 66	G1	Small bowel	SD	No	60	Stop	646	436	−33
16	F, 56	G1	Unknown	SD	Yes	72	H2RA	235	38	−84
17	F, 60	G1	Unknown	SD	Yes	67	Stop	872	421	−52
18	M, 78	G1	Small bowel	SD	Yes	36	Stop	589	380	−35
19	M, 67	G1	Small bowel	SD	No	124	Stop	587	95	−84

Abbreviations: CgA=chromogranin A; F=female; GFR=glomerular filtration rate; H2RA=H₂-receptor antagonist; M=male; NA=not applicable; NED=no evidence of disease; PPI=proton pump inhibitor; SD=stable disease.